腹腔内和静脉内使用细胞抑制剂对实验性播散性卵巢癌大鼠抗肿瘤效果的比较研究
Comparative Study of Antitumor Efficiency of Intraperitoneal and Intravenous Cytostatics in Experimental Rats with Disseminated Ovarian Cancer.
作者信息
Bespalov V G, Vyshinskaya E A, Vasil'eva I N, Semenov A L, Maidin M A, Barakova N V, Stukov A N
机构信息
Research Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, I. N. Petrov Research Institute of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
International Research Centre "Biotechnologies of the Third Millennium", ITMO University (St. Petersburg National Research University of Information Technologies, Mechanics and Optics, St. Petersburg, Russia.
出版信息
Bull Exp Biol Med. 2017 Jan;162(3):383-386. doi: 10.1007/s10517-017-3621-5. Epub 2017 Jan 14.
Antitumor efficiencies of cytostatics dioxadet, cisplatin, mitomycin C, melphalan, and paclitaxel after a single intraperitoneal or intravenous injection in doses of 1.5, 4, 1.5, 2, and 5 mg/kg, respectively, were studied on the model of transplanted ovarian tumor in 124 rats. The antitumor effects were evaluated by the increase in median survival. Dioxadet, cisplatin, and melphalan injected intraperitoneally significantly prolonged the lifespan median - by 79, 88, and 114%, respectively, and were in fact ineffective, when injected intravenously. Intraperitoneal mitomycin C prolonged lifespan median by just 35%, intravenous - by 152%. Paclitaxel injected intraperitoneally and intravenously prolonged the lifespan median by 45 and 81%, respectively.
在124只大鼠的移植性卵巢肿瘤模型上，研究了细胞抑制剂二恶烷、顺铂、丝裂霉素C、美法仑和紫杉醇分别以1.5、4、1.5、2和5mg/kg的剂量单次腹腔内或静脉注射后的抗肿瘤效率。通过中位生存期的增加来评估抗肿瘤效果。腹腔内注射二恶烷、顺铂和美法仑可显著延长中位生存期，分别延长79%、88%和114%，而静脉注射实际上无效。腹腔内注射丝裂霉素C使中位生存期仅延长35%，静脉注射延长152%。腹腔内和静脉内注射紫杉醇分别使中位生存期延长45%和81%。
Zotero 插件